fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Insulin glargine

All injection strengths: general benefit

Toujeo DoubleSTAR · DIN 02493373 · 300U/mL · injection solution-3mL pre-filled pen

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Toujeo DoubleSTAR · DIN 02493373 Manufacturer: Sanofi-Aventis Canada Inc.; listing date 2020-09-30 Health Canada: Marketed since 2020-02-04 · brand TOUJEO DOUBLESTAR · ATC A10AE04 INSULIN GLARGINE · form Solution · route Subcutaneous · ingredients INSULIN GLARGINE 300 UNIT/ML · company Sanofi-aventis canada inc · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Toujeo DoubleSTAR: Formulary list price $52.87 per unit (the source does not state the unit; exact figure $52.8666). What the ministry pays, not the patient.

Ministry pays: $52.8666 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02493373)

Source record
DIN 02493373: Toujeo DoubleSTAR Raw flags: insOH=Y, sec3=Y Item: 682014018; group id 782; item number 1903; lccId None; manufacturer id SAC Source form: Inj Sol-3mL Pref Pen; strength: 300U/mL Recorded listing: General benefit; diabetes medication flag Source prices (unrounded): $52.8666; ministry $52.8666 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02493373 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98339
Shortage status: resolved shortage (ended August 9, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02493373
Shortage record checked October 6, 2026

Other products in the same Health Canada class (A10AE): coverage varies; not interchangeable

  • Insulin degludec (Tresiba): general benefit
  • Insulin detemir (Levemir Penfill): general benefit
Other drugs in the same formulary class (68:20:14 Insulins (Long Acting)) and how they are covered

Matched class: 68:20:14 Insulins (Long Acting)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: INSULIN DEGLUDEC, INSULIN DETEMIR 68:20:14 Insulins (Long Acting)

INSULIN DEGLUDEC

· 3 products · General benefit · strengths: 100U/mL, 200U/mL · Inj Sol-3X5mL Cart Pk, Inj Sol-Flextouch Pref Pen 3x3mL Pk, Inj Sol-Flextouch Pref Pen 5x3mL Pk

INSULIN DETEMIR

· 2 products · General benefit · strengths: 100U/mL · Inj Sol-5x3mL Pk, Inj Sol-Pref Disp Pen 5X3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:14
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS LANTUS [insulin glargine injection (rDNA origin)] is a recombinant human insulin analog indicated for once-daily subcutaneous administration in the treatment of patients over 17 years of age with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. LANTUS is also indicated in the treatment of pediatric patients (˃6 years old) with Type 1 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia . 1.1 Pediatrics Pediatrics (>6 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of LANTUS in pediatric patients over 6 years of age with Type 1 diabetes mellitus has been established. Therefore, Health Canada has authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. In elderly patients with diabetes, the initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemic reactions. https://pdf.hres.ca/dpd_pm/00063800.PDF PM date: December 1, 2021 Source product: LANTUS; DIN 02245689; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.